MedTrace Logo

PP13 and Doppler Study to Predict Preeclampsia

NCT00928213 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2009-06-25

No results posted yet for this study

Summary

Assessment of biochemical and sonographic marker to predict the risk for developing preeclampsia Among biochemical markers are serum level of Placental Protein 13 (PP13) and Placenta Growth factor (PIGF). For sonographic marker Doppler pulsatility Index of the blood flow through the uterine maternal arteries is assessed.

PP13 is produced by the placenta and released to the maternal blood circulation. It has been shown to be an effective serum marker for early onset preeclampsia (Nicolaides KH et al., 2005). The purpose of this study is to combined the assessment of the biochemical markers with Doppler in the first and the second trimester to provide a comprehensive evaluation of various methods for sequential and combined analysis to assess the risk for developing preeclampsia.

Conditions

Interventions

DRUG

Progesterone

40 units daily admission

DRUG

Low molecular weight Heparin

40-80 mg/day

DRUG

No Drug

no treatment

Sponsors & Collaborators

  • Diagnostic Technologies Ltd.

    collaborator INDUSTRY

  • Perkin Elmer Inc.

    collaborator INDUSTRY

  • Medical University of Graz

    collaborator OTHER

  • Ben-Gurion University of the Negev

    lead OTHER

Principal Investigators

  • Reli Hershkovitz, MD · Ben-Gurion University of the Negev

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928213 on ClinicalTrials.gov